| URL | https://www.biopharma-reporter.com/Article/2022/06 |
| Source | BioPharma-Reporter |
| Date Published | 06/23/2022 |
| Author Name | Jane Byrne |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Merck |
| Parent company | Merck |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 50 |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2022 |
| Capital investment ($): | 62 |
| City reshored to: | Verona |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Cancer Therapy |
| What domestic positive factors made reshoring more attractive? | Image/brand, Lead time/Time to market |